Q-omics provides the consensus-scored LRRC27 profile across patient tissues and cancer cell-line models. LRRC27 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LRRC27 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, LRRC27 RNA expression shows 19,406 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, LIHC, and ACC as cancer lineages where LRRC27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC27 survival associations across molecular data types. LRRC27 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC27 RNA expression–survival associations across cancer types. High LRRC27 expression shows favorable associations in MESO, HNSC, UVM, LGG, KIRP and READ. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LRRC27 RNA expression.
This table summarizes LRRC27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC27 shows lower tumor expression in KICH, LUSC and THCA and higher tumor expression in LIHC, COAD and STAD. The LIHC box plot shows higher LRRC27 RNA expression in tumor versus normal tissue (log2 FC = +0.496, t-test p < 0.001).
This table shows molecular features associated with LRRC27 in patient tissues and cancer cell lines. In patient samples, LRRC27 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
